Literature DB >> 30485485

A C-type CpG ODN accelerates wound healing via regulating fibroblasts and immune response.

Lina Li1, Zhenyu Xu2, Jian Zuo2, Jin Ding1.   

Abstract

Abolished or delayed wound healing is a serious problem in clinical surgery, therefore, the new therapy for wound healing is needed. Synthetic oligodeoxynucleotides containing one or more CpG motifs (CpG ODN) has been reported to activate the immune system and improves skin wound healing. The aim of the present study was to evaluate the role of a new C-type CpG ODN in wound healing. We found that the CpG ODN promoted cell proliferation and collagen I production in human skin fibroblasts cells. Besides, we also investigated the effect of CpG ODN on the activation of immune cells. The macrophages and plasmacytoid dendritic cells (pDCs) were incubated with CpG ODN. CpG ODN activated macrophage and pDCs via regulating TLR9/MyD88/NF-κB pathway and TLR9/MyD88/IRF7 pathway, respectively. To further evaluate the effect of CpG ODN on wound healing in vivo a wound healing model was established in mice. The results showed that CpG ODN treatment accelerated wound healing in mice. CpG ODN increased cytokines secretion in wound skin and elevated the ratio of CD4 + and CD8 + T cells in the spleen. Our results showed that CpG ODN accelerated wound healing, which was partly due to the regulation of fibroblasts and immune response. The findings suggested that the CpG ODN might be a proper medicament for the treatment of wound healing.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  immune response; inflammation; synthetic oligodeoxynucleotides containing one or more CpG motifs; wound healing

Year:  2018        PMID: 30485485     DOI: 10.1002/jcb.28061

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  1 in total

Review 1.  Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity.

Authors:  Zhangchi Dongye; Jian Li; Yuzhang Wu
Journal:  Br J Cancer       Date:  2022-07-28       Impact factor: 9.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.